Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novavax, Inc. - Common Stock (NQ:NVAX)

7.458 -0.062 (-0.82%)
Streaming Delayed Price Updated: 3:03 PM EDT, Aug 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novavax, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Thursday's Top 5 Trending Stocks: What's Going On With D-Wave, Novavax, Carvana?
D-Wave Quantum Inc. (NYSE:QBTS), Asset Entities, Inc. (NASDAQ:ASST), Alphabet, Inc. 
Via Benzinga
Novavax Stock Rallies On Upbeat Q1 Earnings, Revised Full-Year Revenue Forecast: Retail’s Elated
The company raised its full-year revenue guidance to between $975 million and $1.025 billion, up from its previous guidance of between $300 million and $350 million. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Uncovering Potential: Novavax's Earnings Preview
 
Via Benzinga
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline
The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine has created uncertainty across the vaccine industry, potentially affecting... 
Via Benzinga
Topics Government
Novavax Tops Weekly Retail Buzz Spike Amid FDA Trial Drama, COVID-19 Vaccine Approval Hopes
Optimism was tempered by a Wall Street Journal report on Friday, which said federal regulators had asked Novavax to conduct another randomized clinical trial of its COVID-19 vaccine. 
Via Stocktwits
Benzinga Bulls And Bears: Netflix, Novavax, Intel — And The Market Begins To Bounce Back
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps
Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full approval decision. 
Via Benzinga
Amphenol Posts Better-Than-Expected Results, Joins SAP, Tesla, Pegasystems And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Novavax Signals Chances Of FDA Approval For Its COVID-19 Vaccine: But Retail Sentiment Wavers
The company announced on Wednesday that it had received formal communication from the FDA in the form of an information request for a “postmarketing commitment” to generate additional clinical data. 
Via Stocktwits
Topics Government
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study
Novavax updated Covid vaccine showed fewer and milder side effects than Pfizer-BioNTech's in a Utah study. 
Via Benzinga
Novavax Retail Traders Rally In Defense After RFK Jr.'s COVID-19 Vaccine Skepticism Sends Stock Tumbling
Kennedy singled out the Novavax COVID-19 shot's single-antigen composition as the reason behind the delay in granting full approval. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
These stocks are gapping in today's session
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
2 Beaten-Down Stocks That Still Aren't Worth Buying
Via The Motley Fool
Topics Cannabis Government Law Enforcement
Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst
Biotech stocks face a tough 2025 with SMid-cap losses up to 40% YTD. BofA cites FDA changes, tariffs, and capital struggles but notes potential opportunities. 
Via Benzinga
Topics World Trade
Novavax Vaccine Approval From FDA In Limbo, Says Report – But Retail Is Hopeful
Though the FDA was set to give full approval to the vaccine, senior leaders at the agency have now said that the company’s application needs more data and is unlikely to be approved soon, The Wall... 
Via Stocktwits
FDA Delays Full Approval Decision On Novavax's COVID-19 Vaccine
Novavax's COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request more data beyond the April 1 deadline. 
Via Benzinga
Moderna, Novavax Shares Are Tumbling Monday: What's Going On?
Vaccine stocks are trading lower Monday following a shakeup at the U.S. Food and Drug Administration. 
Via Benzinga
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies. 
Via Investor's Business Daily
Moderna, Novavax Shares Are Sliding Wednesday: What's Going On?
Vaccine makers Moderna Inc (NASDAQ:MRNA) and Novavax Inc (NASDAQ:NVAX) are facing selling pressure on Wednesday following reports suggesting the Trump administration will end support for Gavi. 
Via Benzinga
Topics Government
2 Beaten-Down Stocks Near Their 52-Week Lows That Aren't Worth Buying
Via The Motley Fool
Nvidia, Tesla Lead Tech Stock Rebound: What's Driving Markets Friday?
Stocks recovered on Friday, with all three major indexes in the green, as the tech sector bounced back from Thursday's losses with NVIDIA Corp. (NASDAQ:NVDA) up 1.37% and Tesla, Inc. (NASDAQ:TSLA) 
Via Benzinga
1 Biotech Stock to Buy in 2025, and 1 to Avoid
Via The Motley Fool
Novavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi Partnership
The company expects to generate $300 million to $350 million in adjusted licensing, royalties, and other revenue in 2025. 
Via Stocktwits
Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships and expects up to $350 million in 2025 revenue. 
Via Benzinga
Novavax Retail Traders Stay Bullish Ahead Of Q4 Print Even As RFK Jr's HHS Leadership Causes Ripples
Kennedy, a longtime vaccine skeptic, now oversees HHS decisions that could impact vaccine makers, making his leadership a wild card for Novavax. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 8 9
...
64 65 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.